Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2094187
下载链接
链接失效反馈官方服务：
资源简介：
1. Primary Endpoints
* Biomarker data suggestive of regorafenib-mediated inhibition of the RAS-RAF- MEK-ERK signal transduction pathway,of various tyrosine kinase receptors and/or of angiogenesis.
* Evaluation of potential relationships between biomarker data and clinical activity.
* Evaluation of a novel biomarker technology (Prometheus COPIA platform)
2. Secondary Endpoints
* Biomarker data suggestive of regorafenib-mediated effects on circulating rare cells.
* Comparison of tumor genetic profiles obtained using DNA isolated from plasma, tumor biopsies and circulating tumor cells.
* Patient safety data
* Pharmacokinetics of regorafenib
* Changes in tumor metabolic activity as measured by PET CT scan (optional)
创建时间：
2011-01-15
